Castle Biosciences (CSTL) EBITDA (2018 - 2026)

Castle Biosciences has reported EBITDA for 9 years, with the latest figure at -$3.1 million in Q2 2026.

• Quarterly EBITDA rose 27.78% year-over-year to -$3.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$32.1 million (down 39.3% YoY) and the FY2025 annual result came in at -$42.8 million, down 593.77% from the prior year.
• EBITDA climbed to -$3.1 million in Q2 2026 per CSTL's latest filing, from -$18.4 million in the prior quarter.
• Over five years, EBITDA peaked at $5.1 million in Q3 2024 and troughed at -$31.5 million in Q1 2023.
• A 5-year average of -$10.9 million and a median of -$6.2 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2024: EBITDA slumped 472.27% in 2022, then surged 171.58% in 2024.
• Over 5 years, EBITDA stood at -$22.8 million in 2022, then jumped by 75.22% to -$5.7 million in 2023, then jumped by 171.58% to $4.0 million in 2024, then plunged by 194.49% to -$3.8 million in 2025, then increased by 19.78% to -$3.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.1 million, -$18.4 million, and -$3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.